Erlinda C. Capili-Rosenkranz, ARNP

Erlinda Capili-Rosenkranz practices at Cleveland Clinic Florida - Weston in Weston, Florida.

Erlinda Capili-Rosenkranz's NPI, 1265494173, was assigned on April 5, 2006. Erlinda Capili-Rosenkranz holds Florida license ARNP1142982.

Erlinda Capili-Rosenkranz's primary practice is Cleveland Clinic Florida - Weston, at 2950 Cleveland Clinic Blvd, Weston, FL 33331 in Broward County. The practice phone is (954) 689-5000.

Erlinda Capili-Rosenkranz's primary practice is Cleveland Clinic Florida - Weston in Weston, Florida. Erlinda Capili-Rosenkranz is also affiliated with Cleveland Clinic Weston Hospital. The medical group on file is Cleveland Clinic Florida.

Dmand AI tracks the electronic health record (EHR) system at each site where Erlinda Capili-Rosenkranz practices. Vendor and product names are available with a free account.

Nurse practitioner is Erlinda Capili-Rosenkranz's primary specialty in the NPI Registry, under taxonomy code 363L00000X. Erlinda Capili-Rosenkranz is licensed in Florida.

Dmand AI lists chronic diabetes, diabetic emergency, enlarged thyroid, high cholesterol, osteoporosis, underactive thyroid and vitamin d deficiency among the conditions Erlinda Capili-Rosenkranz treats.

CMS data shows 517 Medicare services from Erlinda Capili-Rosenkranz across 6 procedure codes in 2024, for 225 Medicare patients. Medicare paid $28,695 for them.

CMS counts 225 Medicare patients who saw Erlinda Capili-Rosenkranz in 2024. The largest group is 65 to 74, with 103 patients. 75% of them have diabetes, and 75% have high blood pressure. 13% are also on Medicaid. Their average risk score is 2.02, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Erlinda Capili-Rosenkranz's median patient age at 65, with 56% women.

In 2024, Erlinda Capili-Rosenkranz wrote 5,320 Medicare Part D claims for 998 patients. 25% of them were for generic drugs. CMS names the drug for 5,042 of them, across 61 drugs with 11 or more claims each, at $2,867,498 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Erlinda Capili-Rosenkranz for performance year 2024, reported through an alternative payment model (APM). Erlinda Capili-Rosenkranz accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 53 general payments to Erlinda Capili-Rosenkranz from 11 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Boehringer Ingelheim Pharmaceuticals, Inc. paid the most, $506.